Menu
Menu
Would you be able to spot your clients’ recreational use of psychedelics? What does psychedelic use mean for them (and you) in therapy? Would any of your clients benefit from a psychedelic experience? How will you know? How will you navigate the ethical dilemmas that may arise in session?
Many of us were taught nothing about psychedelics, or were given out-of-date information based on early Prohibition era stories and policies. Psychedelic-assisted psychotherapy is effective in the treatment of a variety of mental health conditions, and the FDA has both approved phase III clinical trials and expanded access. But there are gaps between clinician awareness of psychedelic use, how psychedelics are used in carefully designed clinical trials, and how your clients use them in the real world.
Complete this online training to bridge those gaps and confidently address your clients’ questions and experiences. You’ll acquire the skills you need to navigate common ethical dilemmas that may arise from talking with your clients about possibly illegal activity.
By completing this course, you’ll discover why clients use psychedelic substances and how this may impact their treatment.
In this workshop, you will learn:
Purchase today, and get need-to-know information on psychedelic substances, a better understanding of the research and navigate these changing times!
| File type | File name | Number of pages | |
|---|---|---|---|
| Manual - Psychedelics, Hallucinogens and Entheogens (2.6 MB) | 77 Pages | Available after Purchase | |
| Modules 1-4 Manual | Psychedelics, Hallucinogens and Entheogens - French (2.60 MB) | 77 Pages | Available after Purchase | |
| Modules 1-4 Manual | Psychedelics, Hallucinogens and Entheogens - Italian (2.60 MB) | 77 Pages | Available after Purchase |
Peter H Addy, PhD, LPC, LMHC, has studied psychedelic substances and states and consciousness for 15 years. He earned a PhD in clinical psychology studying transcendence, wholeness, and transformation and conducted one of the earliest studies of the atypical psychedelic plant Salvia divinorum in humans. He continued refining his research and clinical skills at Yale University where he studied Salvia and other atypical psychedelics and co-founded the Yale Psychedelic Science Group. He has completed postdoctoral training in substance use disorder treatment, participated in non-directive harm reduction and integration training at Burning Man, and traveled to Mexico to learn about indigenous use of psychedelic plants among the Mazatec people. He is currently a psychotherapist in private practice in Washington and Oregon.
Dr. Addy has presented internationally on a variety of subjects related to spirituality and transpersonal states, psychedelic science, and research methodology. Participants consistently regarded his talks as informative, accessible, and humorous. He has written numerous scientific articles, book chapters, and popular press articles on typical and atypical psychedelics, substance abuse, and spirituality.
Speaker Disclosures:
Financial: Dr. Peter Addy maintains a private practice and has an employment relationship with the Synaptic Training Institute. He receives a speaking honorarium and recording royalties from PESI, Inc. He has no relevant financial relationships with ineligible organizations.
Non-financial: Dr. Peter Addy has no relevant non-financial relationships.
Types of Psychedelic Substances: What You Need to Know
History & Context of Psychedelic Use: The Research
Legal Avenues for Experiencing Psychedelics: Paths Clients May Take
Ethical Considerations for Your Clients
Ethical Considerations in the Therapy Room
Psychotherapy Preparation & Integration
Please wait ...